Overview of ifosfamide in small cell lung cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Ifosfamide, an analogue of the alkylating agent cyclophosphamide, is one of the most active agents in the treatment of small cell lung cancer (SCLC). As a single agent, the drug produces a greater than 50% objective response rate. Recent studies using ifosfamide in combination with other active agents, ie, cisplatin, carboplatin, and etoposide, in the treatment of limited-stage and extensive-stage SCLC have achieved high overall response rates and complete responses (CRs). However, the CR rate is higher in limited-disease patients. Additional studies are needed with the various ifosfamide-containing regimens to precisely define their role in the treatment of SCLC in both limited-disease and extensive disease patients.

Original languageEnglish (US)
Pages (from-to)59-67
Number of pages9
JournalSeminars in oncology
Volume19
Issue number1 SUPPL. 1
StatePublished - Feb 1992

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Overview of ifosfamide in small cell lung cancer'. Together they form a unique fingerprint.

Cite this